Social Anxiety Disorder Market Size is expected to grow by 2032, estimates DelveInsight

DelveInsight’s “Social Anxiety Disorder Market Insights, Epidemiology, and Market Forecast – 2032” report delivers an in-depth understanding of the Social Anxiety Disorder, historical and forecasted epidemiology as well as the Social Anxiety Disorder market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Explore the intricate details of the Social Anxiety Disorder Market: Uncover drug uptake, treatment dynamics, and epidemiological trends with our comprehensive Social Anxiety Disorder Market Forecast. Click here to stay ahead in healthcare innovation @ Social Anxiety Disorder Market Size

 

Key Takeaways from the Social Anxiety Disorder Market Report

April 2024:- VistaGen Therapeutics Inc.- US, Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial of Fasedienol Nasal Spray for the Acute Treatment of Anxiety Induced by a Public Speaking Challenge in Adult Subjects With Social Anxiety Disorder, With an Open-Label Extension (PALISADE-3).
According to National Institute of Mental Health (NIMH), about 1 in 8 people (12.1%) experience socialAnxiety Disorder at some time in their life and in a given year. According to the U.S. National Institutes ofHealth (NIH), SAD is the third most common psychiatric condition after depression and substance abuse. Ofadults with social anxiety disorder in the past year, an estimated 29.9% had serious impairment.
As per Anxiety and Depression Association of America (ADAA) 2021, social anxiety disorder affects around15million adults, or 6.8% of US population. Many people frequently misdiagnosed as a result of the disease.thirty-six of people with social anxiety disorder experience symptoms for 10 years or more before seekingcare, according to a 2007 ADAA survey.
According to Cambridge University (2020), epidemiologic surveys conducted across Europe indicated thatthe lifetime prevalence of Social anxiety disorder in general population is close to 7%.
According to the analysis, females are more frequently diagnosed with SAD compared to males.
The leading Social Anxiety Disorder Companies such as VistaGen Therapeutics Inc., EmpowerPharm Inc., and others.
Promising Social Anxiety Disorder Therapies such as Fasedienol Nasal Spray, Cannabidiol oral solution, Sunflower Lecithin Oil in Capsule, and others.

Delve deep into the Social Anxiety Disorder Market Landscape: Analyze drug adoption, treatment paradigms, and epidemiological shifts in our detailed Social Anxiety Disorder Market Forecast. Click here to shape the future @ Social Anxiety Disorder Epidemiology Insights

 

Social Anxiety Disorder Overview

Social Anxiety disorder (also called Social Phobia; SAD) is the most common mental health condition which causes extreme fear in social settings, and an intense, persistent fear of being watched and judged by others. People with social anxiety disorder have trouble talking to people, meeting new people, attend social gatherings and can also affect day-to-day activities. Social anxiety disorder can make a person fear from being judged or scrutinized by others. Patients may understand that their fears are irrational or unreasonable, but feel powerless to overcome them.

Social Anxiety Disorder Epidemiology Insights

Total Prevalent Cases
Severity specific cases
Treated cases
Social Anxiety Disorder Cases by age group
Total Diagnosed Cases

Navigate the complexities of the Social Anxiety Disorder Market: Gain insights into drug trends, treatment scenarios, and epidemiological data through our insightful Social Anxiety Disorder Market Forecast. Click here to get more insights @ Social Anxiety Disorder Treatment Market

 

Social Anxiety Disorder Market Insights

GABAergics: Pregablin and gabapentin are GABAergic drugs proven beneficial for treating SAD. These agent havesimilar pharmacological profiles, working as calcium modulators to inhibit excitatory neurotransmitter release.Pregablin has a quicker onset of action that the FDA-approved antidepressants.

Social Anxiety Disorder Treatment Market Landscape

The Social Anxiety Disorder treatment includes psychological and pharmacological options. The psychological intervention termed cognitive-behavioral therapy (CBT) is used to help patients face barriers directly through exposure techniques, relaxation techniques, and training in social and conversational skills. It is always recommended that CBT should be always implemented ahead of pharmacologic therapy. Patients who manage their symptoms with psychological and pharmacologic treatment are more likely to achieve continued symptom-improvement benefits.

Unlock insights into the Social Anxiety Disorder Market: discover drug uptake patterns, treatment landscapes, and epidemiological insights with our exclusive Social Anxiety Disorder Market Forecast. Click here @ Social Anxiety Disorder Market Drivers and Barriers

 

Social Anxiety Disorder Market Dynamics

The Social Anxiety Disorder market dynamics is anticipated to change in the coming years owing to the improvement in the research and development undertaking. Major Pharma giants are thoroughly working toward the development of new treatment therapies for this indication, in order to provide better relief for the symptoms and hence improve the Quality of life (QoL) of patients with SAD.

Social Anxiety Disorder Drugs Uptake

Vistagen Therapeutics is currently developing its lead product candidate PH94B nasal spray and is fundamentally different from all current drug treatments for SAD. PH94B binds to nasal chemosensory receptors which activates neural circuits that leads to rapid suppression of fear and anxiety. The drug is currently being studied in three Phase III (NCT05030350; NCT05011396; NCT04754802) clinical studies for the treatment of acute social anxiety disorder. The FDA has granted Fast-track designation for development of PH94B as a potential fast-acting acute treatment of SAD.
BNC210 is a selective NAM of the α7 receptor being developed for the acute treatment of Social Anxiety Disorder. BNC 210 is Bionomics proprietary molecule in development for the treatment of SAD, posttraumatic stress disorder (PTSD) and anxiety disorders. It has a novel mechanism of action and extensive clinical and non-clinical studies have shown several properties which may be useful to treat SAD. Bionomics expects to initiate Phase II study for BNC 210 for acute treatment of SAD by 2021 and anticipating topline results by the end of 2022

Social Anxiety Disorder Market Drivers

Less competitive scenarios
Fast-acting innovative emerging therapies
Increasing awareness and Prevalence

 

Social Anxiety Disorder Market Barriers

Lack of robust pipeline
Barriers to treatment
Psychological and financial burden

 

Scope of the Social Anxiety Disorder Market Report

Coverage- 7MM
Social Anxiety Disorder Companies- VistaGen Therapeutics Inc., EmpowerPharm Inc., and others.
Social Anxiety Disorder Therapies- Fasedienol Nasal Spray, Cannabidiol oral solution, Sunflower Lecithin Oil in Capsule, and others.
Social Anxiety Disorder Market Dynamics: Social Anxiety Disorder Market drivers and Social Anxiety Disorder Market Barriers
Social Anxiety Disorder Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Social Anxiety Disorder Unmet Needs, KOL’s views, Analyst’s views, Social Anxiety Disorder Market Access and Reimbursement

Gain a strategic edge in the Social Anxiety Disorder Market: explore comprehensive drug insights, treatment updates, and epidemiological forecasts in our in-depth Social Anxiety Disorder Market Forecast. Click here to lead in advancements @ Social Anxiety Disorder Clinical Trials Assessment

Table of Content

1. Key Insights

2. Executive Summary of Social Anxiety Disorder (SAD)

3. Competitive Intelligence Analysis for Social Anxiety Disorder (SAD)

4. Social Anxiety Disorder (SAD): Market Overview at a Glance

5. Social Anxiety Disorder (SAD): Disease Background and Overview

6. Patient Journey

7. Social Anxiety Disorder (SAD) Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Social Anxiety Disorder (SAD) Unmet Needs

10. Key Endpoints of Social Anxiety Disorder (SAD) Treatment

11. Social Anxiety Disorder (SAD) Marketed Products

12. Social Anxiety Disorder (SAD) Emerging Therapies

13. Social Anxiety Disorder (SAD): Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Social Anxiety Disorder (SAD)

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Stay up to date
Register now to get updates on promotions and coupons

Shopping cart

×